Supplemental Figure 4

```
        FR1-IMGT          CDR1-IMGT      FR2-IMGT     CDR2-IMGT                FR3-IMGT                CDR3-IMGT   FR4-IMGT
         (1-26)            (27-38)       (39-55)      (56-65)                 (66-104)                (105-117)   (118-128)
     A          B          BC        C        C'      C'C"      C"       D          E         F        FG          G
   (1-15)     (16-26)     (27-38)   (39-46)  (47-55)   (56-65)   (66-74)  (75-84)   (85-96)   (97-104)  (105-117)   (118-128)
 ----------> ---------->            -------> -------> -------> -------> -------> ---------> ------->            ---------->
1        10  15 16    23 26 27       38 3941  46 47     55 56      65 66     74 75      84 85  89    96 97   104 105 11112 117 118     128
|........|....| |......|..| |..........| |.|....| |.......| |........| |.......| |........| |...|......| |......| |.....||....| |.........|

.IQMTQSPSSLSASV GDRVTITCRAS QGI......SSA LAWYQQKP GKAPKLLIY DA.......S SLESGVP.S RFSGSG..SG TDFTLTISSLQP EDFATYYC QQFNS....YPLT FGGGTKVEIK.
```

IMGT DomainGapAlign output indicating LLIYDASSLESGVPSR sequence spans CDR 2 .

853.95 Da @ 37.7 min



Supplemental Figure 4 Screen captures of PEAKS and DomainGapAlign indicating identification of CDR 2 tryptic peptide (LLIYDASSLESGVPSR) for the serial samples monitored in Figures 3 and 4.